|
Patent landscape, scope, and claims: |
United States Patent 7,659,302 Scope and Claims: What Method-of-Treatment Coverage Does It Provide for Stereomerically Pure (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-dione?
United States Patent 7,659,302 covers method-of-treating inflammatory and immune-mediated diseases using stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione (including pharmaceutically acceptable salts) with defined dose ranges and multiple administration routes, plus combination use with antihistamines and anti-inflammatory drugs/steroids.
What matters for licensing, freedom-to-operate, and litigation posture: the claim set is structured to capture (i) broad indication coverage, (ii) broad dosing envelopes, (iii) multiple delivery routes, and (iv) standard-of-care co-therapy, while narrowing the active ingredient to a specific enantiopure (+) stereoisomer.
What is the core claim scope of US Patent 7,659,302 (enantiopure (+) isomer, specific indications, and treatment methods)?
Claim 1: Broad method-of-treatment for multiple inflammatory/immune diseases
Claim 1 is the independent anchor. It covers:
- Method of treating:
- depression
- inflammatory skin disease
- psoriasis
- atopic dermatitis
- contact dermatitis
- rheumatoid arthritis
- osteoarthritis
- systemic lupus erythematosus
- inflammatory bowel disease
- Crohn’s disease
- Behcet’s disease
- colitis
- Treatment comprises administering to a patient in need:
- a therapeutically effective amount of:
- stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or
- a pharmaceutically acceptable salt of that compound.
Key scope drivers
- The claim uses “method of treating [multi-disease list]” language, so infringement does not require a single specific indication. Coverage turns on whether the accused conduct is a treatment for any listed disease.
- The active ingredient restriction is enantiomeric purity: “stereomerically pure (+)”. This can be a strong differentiator versus racemic or (−)-dominant products.
- Salts are included, expanding coverage beyond the free base/neutral form.
Claim structure implications
- Because the claim is method-of-use, it can be infringed by prescribing/dispensing and administration consistent with the claimed method.
- The claim does not require a particular formulation other than what later dependent claims specify.
Which indications are explicitly covered, and how broad is the indication list (depression, psoriasis, dermatoses, autoimmune, IBD)?
Explicit disease coverage (Claim 1 and Claim 10)
- Depression is explicitly listed in Claim 1.
- Skin inflammatory diseases are explicitly covered:
- inflammatory skin disease
- psoriasis
- atopic dermatitis
- contact dermatitis
- Rheumatologic and autoimmune diseases:
- rheumatoid arthritis
- osteoarthritis
- systemic lupus erythematosus
- Behcet’s disease
- Gastrointestinal inflammatory diseases:
- inflammatory bowel disease
- Crohn’s disease
- colitis
Dedicated psoriasis method (Claim 10)
Claim 10 narrows to:
- “A method of treating psoriasis”
- administering therapeutically effective amount of the stereomerically pure (+) compound.
Practical consequence
- If a generic or competitor challenges the breadth of the multi-indication list, Claim 10 provides a standalone psoriasis hook with the same enantiopure active ingredient requirement.
What administration routes are claimed (parenteral, transdermal, mucosal, nasal, buccal, sublingual, oral) and what is the oral sub-scope?
Claim 4: Multi-route administration
Claim 4 expands the method to:
- administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, or orally.
This is a classic “route-inclusive” structure that supports infringement arguments across common development pathways (oral tablets/capsules, injectables, topical/transdermal, transmucosal forms).
Claims 5–6: Oral route + dosage form
- Claim 5: patient receives the stereomerically pure (+) compound orally.
- Claim 6: administered orally as a tablet or capsule.
Practical consequence
- Oral solid dose products are explicitly inside the claim set. If a competitor launches a pill/capsule product with the same enantiopure stereoisomer, the claim pathway is direct.
What dose ranges are covered (1–1000 mg/day; narrower windows; specific daily regimens)?
General dose envelope (Claims 7–9)
- Claim 7: ~1 mg to ~1000 mg per day
- Claim 8: ~5 mg to ~500 mg per day
- Claim 9: ~10 mg to ~200 mg per day
Psoriasis-specific further narrowing (Claims 14–17)
- Claim 14: ~1 mg to ~1000 mg per day
- Claim 15: ~5 mg to ~500 mg per day
- Claim 16: ~10 mg to ~200 mg per day
- Claim 17: ~20 mg to ~40 mg per day
Specific dosing regimens (Claims 18–19)
- Claim 18: ~20 mg twice daily
- Claim 19: ~40 mg once daily
Claim-coverage significance
- The broad method claims (Claim 1) cover any “therapeutically effective amount,” but the dependent claims create numerical infringement targets.
- If an accused product uses a dosing schedule that lands inside 20–40 mg/day (and especially the BID vs QD formats), the odds of mapping to dependent claims increase.
What does the combination-therapy language cover (antihistamines, anti-inflammatories, NSAIDs, steroids)?
Claim 2 and Claim 20: Co-therapy included
- Claim 2: Claim 1 further comprising administering to a patient:
- an antihistamine, and/or
- an anti-inflammatory drug, and/or
- a non-steroid anti-inflammatory drug, and/or
- a steroid.
- Claim 20 mirrors the combination language for the independent method pathway in Claim 10.
Practical consequence
- The claim set supports infringement theories where the enantiopure (+) compound is used alongside routine symptom-management or anti-inflammatory regimens.
- The combination is described at a level that can be satisfied even if the co-therapy is not the main active ingredient in a single formulation, as long as the accused conduct results in administration of the co-therapeutic classes in combination with the claimed compound.
How tight is the enantiomer limitation (what does “stereomerically pure (+)” do to patent scope and design-arounds)?
Enantiopurity as the principal chemical limitation
The claimed active ingredient is:
- stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
- or a pharmaceutically acceptable salt of that stereoisomer.
Claim 11 reinforces enantiomer purity for psoriasis
Claim 11: compound is “substantially free of (−) isomer.”
Design-around implications
- A competitor can attempt to avoid coverage by shifting stereoisomer composition. The claim language does not define a numerical % threshold for “substantially free,” but it creates a chemical boundary that can become the center of infringement and validity disputes.
- If an accused product is racemic or enriched in the (−) isomer, the patentee’s best path is to show it still meets “stereomerically pure (+)” or “substantially free of (−)” requirements, which is typically evidence-driven.
What is the infringement map for different generic/product scenarios (oral solids, different routes, racemic vs enantiopure, dose changes, monotherapy vs combination)?
Scenario A: Oral tablet/capsule using enantiopure (+)
Highest direct risk:
- Satisfies Claim 1 + Claim 5 + Claim 6.
- If the product targets psoriasis within 20–40 mg/day and uses 20 mg BID or 40 mg QD, it can map to Claims 17–19.
Scenario B: Same compound but different route (injectable, topical, nasal)
Still high risk:
- Claim 4 explicitly includes multiple routes, including parenteral and topical/transdermal and nasal.
Scenario C: Oral product with mixture/racemate rather than “stereomerically pure (+)”
Risk turns on chemical composition:
- The claims are enantiomer-limited. Avoiding the enantiopure component is the key design-around concept, but Claim 11’s “substantially free of (−)” can still capture enriched (+) products.
Scenario D: Same compound and same enantiomeric purity but different dose
Method claim remains:
- Claim 1 requires “therapeutically effective amount” and may still be infringed.
- Dependent claims with specific mg/day ranges might not be met, but the independent claim can still reach.
Scenario E: Monotherapy vs combination
Still within the estate:
- The independent method does not require combination.
- Combination language in Claims 2 and 20 creates additional infringement hooks if co-therapies are used.
What formulation and manufacturing elements are NOT claimed in the provided claim set (and how does that affect freedom-to-operate)?
Based strictly on the provided claims, the estate does not expressly claim:
- specific polymorphs or solid-state forms,
- manufacturing processes,
- excipient compositions,
- particle size or bioavailability parameters,
- specific salt identity (it says pharmaceutically acceptable salt generally),
- specific titration conditions or stereochemical synthesis steps.
The claims are primarily method-of-treatment and route/dose/regimen dependent. That means:
- A different formulation or manufacturing method does not necessarily avoid infringement if the same enantiopure (+) compound is administered for a covered indication at a therapeutically effective dose.
How strong is the patent estate for this compound’s therapeutic use (scope breadth from disease list + routes + dosing)?
Strength indicators based on claim drafting
- Multi-indication breadth: one independent claim covers a wide set of inflammatory/immune conditions, with explicit derm, rheum, and GI conditions plus depression.
- Route breadth: Claim 4 covers most major routes.
- Dose coverage: broad mg/day ranges in both independent and dependent structures.
- Enantiopurity narrowing: limits chemical scope but provides a potentially litigable discriminator versus racemic or other stereochemical variants.
- Combination compatibility: dependent claims permit co-therapy rather than requiring monotherapy.
Key litigation focus points implied by the claims
- Whether an accused product is stereomerically pure (+) or “substantially free” of (−).
- Whether physicians/dispensers/administer the drug for a covered disease (or whether marketing induces such use).
- Whether dosing and regimen map to dependent claim ranges (especially 20–40 mg/day and BID/QD schedules).
What does the claims set suggest about related patent families and likely US/foreign coverage themes (method-of-use vs compound vs stereochemical claims)?
The claims presented are method-of-treatment and enantiomer-specific. In most stereoisomer-driven programs, separate families frequently exist around:
- compound composition and stereochemical preparation,
- enantiopure drug substance and salt identity,
- formulation and dosage form,
- additional method-of-use indications,
- combination regimens.
Given only the claims text provided, the most actionable inference is limited: US 7,659,302 appears intended to lock down therapeutic administration rather than manufacturing.
How does US Patent 7,659,302 likely interact with Paragraph IV and generic entry risk (method-of-use infringement vs composition carve-outs)?
Risk pattern for generics
- If a generic files an ANDA for a drug that is the same chemical entity (or salt) and is marketed/used for covered indications, the method-of-use claims create exposure.
- If the generic is enantiomerically different (not stereomerically pure (+)), the chemical limitation can be a central defense.
Timing question: when does exclusivity end?
The provided input includes only the claims, not:
- filing date,
- earliest priority date,
- patent term adjustment,
- patent term expiration,
- FDA exclusivity periods,
- Orange Book listings for the specific NDA/ANDA.
No definitive “expiration” analysis can be produced from the provided record.
What Orange Book status questions and FDA status questions would be determinative, given these claims?
This claim set is method-of-use and enantiopure-specific, so the key regulatory mapping questions in practice are:
- whether the covered product in the Orange Book is the same enantiomeric form,
- whether labels include the covered indications and routes,
- whether FDA approvals include salts and/or enantiopure specs that align with “stereomerically pure (+).”
However, the provided input does not include any FDA listing identifiers or label details, so they cannot be mapped to 7,659,302 here.
Key Takeaways
- US 7,659,302 is a broad enantiopure (+) stereomer method-of-treatment patent covering a wide list of inflammatory, immune-mediated, and related conditions, including psoriasis and IBD/Crohn’s/colitis, plus depression.
- Coverage spans multiple administration routes (including oral), wide dosing ranges, and specific regimens for psoriasis (notably 20–40 mg/day, including 20 mg BID and 40 mg QD).
- The chemical boundary is the central limiter: “stereomerically pure (+)” and for psoriasis “substantially free of (−) isomer.”
- Dependent claims add infringement hooks for combination use with common antihistamine and anti-inflammatory/steroid therapies.
- Based only on the claims text, the estate is positioned to capture therapeutic administration rather than specific formulation/manufacturing steps.
FAQs
1) Does US 7,659,302 require a specific formulation (tablet/capsule) or only a therapeutically effective amount?
The independent claim requires only administering a therapeutically effective amount of the enantiopure (+) compound (or salt). Tablet/capsule limitations appear only in dependent claims.
2) Can the patent be infringed via topical or injectable dosing, or is it limited to oral drugs?
Claim 4 includes parenteral, transdermal, mucosal, nasal, buccal, sublingual, and oral administration.
3) What is the strongest design-around lever implied by the claims?
Avoiding the enantiopure (+) requirement, including avoiding products that are “substantially free of (−)” for psoriasis.
4) If an accused product uses the same drug but treats only one disease not listed, is it still covered?
The claims require treatment for diseases in the list. If the use is for non-listed conditions, the asserted method claims would not map.
5) Do the combination claims require that the antihistamine/NSAID/steroid be included in the same product?
The claim text says the method “comprising administering” those drug classes; it does not require a single combination formulation.
References (APA)
- United States Patent 7,659,302 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
